Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
CNY48.31
+1.72 (+3.69%)
CN SHZ Healthcare Biotechnology
Address
No. 182, Beijing Road 610100
Chengdu, ZJ, CN
Chengdu, ZJ, CN
CEO
Hermit Zhang
Website
kangh.com
IPO
2020-06-16
ISIN CNE100003Y57
Description
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Products Co., Ltd. was founded in 2004 and is based in Chengdu, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY48.31
+1.72 (+3.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.45
Float Shares
73.88M
Free Float %
56.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.10% | -7.30% | -16.36% | -30.66% | -41.65% | -33.93% | -17.30% | -40.06% | -77.72% | +5.99% | +5.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
48.31
DCF (Unlevered)
45.49
-5.8%
DCF (Levered)
25.07
-48.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
12.91
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-18.6% Q1'26: +25.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-44.2% Q1'26: +31.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+23.7% Q1'26: +7.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+22.6% ★ Q1'26: +17.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+8.8% ★ Q1'26: +4.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.3% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.41× ★ Q1'26: 0.25× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.04B
est: 1.07B (-2.9%)
|
1.29B
est: 1.31B (-1.2%)
|
1.45B
est: 1.57B (-8.1%)
|
1.58B
est: 1.68B (-6.3%)
|
1.43B
est: 1.91B (-25.0%)
|
1.17B
est: 1.19B (-2.2%)
|
1.31B
1.31B – 1.31B
+9.6% YoY
|
1.45B
1.45B – 1.45B
+11.2% YoY
|
1.58B
1.55B – 1.61B
+8.6% YoY
|
| EBITDA |
478.18M
est: 474.94M (+0.7%)
|
629.00M
est: 580.94M (+8.3%)
|
643.37M
est: 698.97M (-8.0%)
|
651.50M
est: 691.13M (-5.7%)
|
595.04M
est: 783.04M (-24.0%)
|
340.19M
est: 489.04M (-30.4%)
|
536.21M
536.21M – 536.21M
+9.6% YoY
|
596.30M
596.30M – 596.30M
+11.2% YoY
|
647.62M
634.48M – 660.76M
+8.6% YoY
|
| EBIT |
465.92M
est: 448.87M (+3.8%)
|
613.96M
est: 549.06M (+11.8%)
|
611.84M
est: 660.61M (-7.4%)
|
600.49M
est: 631.87M (-5.0%)
|
531.64M
est: 715.90M (-25.7%)
|
263.42M
est: 447.11M (-41.1%)
|
490.23M
490.23M – 490.23M
+9.6% YoY
|
545.17M
545.17M – 545.17M
+11.2% YoY
|
592.09M
580.08M – 604.10M
+8.6% YoY
|
| Net Income |
408.05M
est: 408.43M (-0.1%)
|
829.48M
est: 702.35M (+18.1%)
|
598.07M
est: 720.17M (-17.0%)
|
509.22M
est: 552.98M (-7.9%)
|
398.65M
est: 727.71M (-45.2%)
|
219.90M
est: 213.76M (+2.9%)
|
265.09M
265.09M – 265.09M
+24.0% YoY
|
310.58M
310.58M – 310.58M
+17.2% YoY
|
356.06M
356.06M – 356.06M
+14.6% YoY
|
| SGA |
444.98M
est: 429.52M (+3.6%)
|
498.42M
est: 525.38M (-5.1%)
|
510.78M
est: 632.13M (-19.2%)
|
601.15M
est: 692.96M (-13.2%)
|
658.40M
est: 785.11M (-16.1%)
|
556.65M
est: 490.34M (+13.5%)
|
537.63M
537.63M – 537.63M
+9.6% YoY
|
597.88M
597.88M – 597.88M
+11.2% YoY
|
649.34M
636.16M – 662.51M
+8.6% YoY
|
| EPS |
3.45
est: 3.10 (+11.2%)
|
6.15
est: 5.33 (+15.3%)
|
4.47
est: 5.47 (-18.3%)
|
3.81
est: 4.26 (-10.5%)
|
3.03
est: 5.60 (-45.9%)
|
1.69
est: 1.65 (+2.7%)
|
2.04
2.04 – 2.04
+24.0% YoY
|
2.39
2.39 – 2.39
+17.2% YoY
|
2.74
2.74 – 2.74
+14.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
332.59M
OE per share TTM
2.56
Owner's Yield
5.36%
Maintenance CapEx ratio
36.24%
Maint CapEx / Avg PPE
53.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 92.4K | 0.65% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 122.0K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 79.0K | 0.29% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 14.1K | 0.46% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 18.3K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.1K | 0.48% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 67.3K | 0.28% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 900.8K | 0.06% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 12.2K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 867.0K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
424.9K
Shares Outstanding
129.95M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fu Wang | Vice President | — | male |
| Hongbo Wu | President & Non-Independent Director | — | male |
| Huaigong Chen | Vice President & Quality Manager | — | male |
| Ping Liu | Accounting Supervisor | — | — |
| Wennian Wu | Vice President, Chief Financial Officer, Secretary of the Board & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300841.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
